Login to Your Account



Other News To Note


Friday, June 10, 2011
Emergent BioSolutions Inc., of Rockville, Md., said investigational anthrax vaccine NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant) was granted fast-track status by the FDA. The candidate, also known as aV7909, consists of BioThrax (anthrax vaccine adsorbed) in combination with an immunostimulatory oligodeoxynucleotide compound, CPG 7909, and is being evaluated in a Phase Ib trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription